罗沙司他致甲状腺功能减退1例

杨云娇; 王曦; 闫雪莲; 谢海雁

doi:10.16766/j.cnki.issn.1674-4152.003698

罗沙司他致甲状腺功能减退1例

doi: 10.16766/j.cnki.issn.1674-4152.003698

1.
中国医学科学院北京协和医院风湿免疫科，北京 100032
2.
中国医学科学院北京协和医院内分泌科，北京 100032
3.
中国医学科学院北京协和医院药剂科，北京 100730
4.
中国医学科学院，北京协和医院保健医疗部，北京 100032

基金项目:

北京协和医院沉淀科研经费整合委托项目基金 ZC201904826

详细信息

通讯作者:
谢海雁，E-mail：xiehy@pumch.cn

中图分类号: R581.2 R969.3
计量
- 文章访问数: 25
- HTML全文浏览量: 11
- PDF下载量: 3
- 被引次数: 0
出版历程
- 收稿日期: 2024-02-11

Hypothyroidism caused by roxadustat: a case report

1.
Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100032, China

摘要

摘要: 本文报道了1例缺氧诱导因子脯氨酰羟化酶抑制剂罗沙司他治疗肾性贫血导致的甲状腺功能减退。患者男性，86岁，因“诊断慢性肾功能不全10年，少言、进食减少3周”就诊。用药4个月后出现甲状腺功能减退的症状及实验室检查异常。停用罗沙司他1周后甲状腺功能逐渐恢复正常。提示对接受罗沙司他治疗的患者，用药后应定期监测甲状腺功能，必要时停药或使用甲状腺激素替代治疗。
- 肾性贫血 /
- 罗沙司他 /
- 甲状腺功能
Abstract: This article reports a case of hypothyroidism caused by roxadustat, a prolyl-hydroxylase inhibitor, used to treat renal anemia. An 86-year-old male with a 10-year history of chronic renal insufficiency with reduced speech and food intake for 3 weeks. After 4 months of medication, symptoms of hypothyroidism and abnormal laboratory tests appeared. After discontinuing roxadustat for one week, his thyroid function gradually normalized. For patients receiving roxadustat treatment, regular thyroid function monitoring is essential, and discontinuation or thyroid hormone replacement therapy should be considered if necessary.
- Renal anemia /
- Roxadustat /
- Thyroid function
利益冲突 无

HTML全文

表 1 患者甲状腺功能及用药情况

Table 1. The thyroid function and medication situation in patients

项目	2023年5月	2023年7月	2023年11月14日	2023年11月22日	2022年12月22日	2024年1月1日	2024年2月18日
TSH(0.23~4.43 μIU/mL)	4.97	ND	0.12	2.99	1.40	4.57	4.00
FT3(1.8~4.1 pg/mL)	2.01	ND	0.53	1.67	1.58	1.91	1.75
FT4(0.81~1.89 ng/dL)	1.04	ND	0.34	0.65	0.53	0.72	0.82
T3(0.66~1.92 ng/mL)	0.70	ND	0.20	0.45	0.39	0.55	0.33
T4(4.3~12.5 mg/dL)	7.7	ND	1.3	3.2	3.0	4.0	4.0
优甲乐(mg/d)	-	-		6.25	18.75	18.75	18.75
罗沙司他(mg，每周3次)	-	70	70	70	停用1周	恢复70	70
注：ND表示未检测，“-”表示未使用。

下载: 导出CSV

参考文献(15)

[1]	吕晴, 陈卫东, 刘磊. 维持性血液透析患者肾性贫血的多因素分析及相关性研究[J]. 中华全科医学, 2021, 19(5): 871-874. doi: 10.16766/j.cnki.issn.1674-4152.001938 LYU Q, CHEN W D, LIU L. Multivariate analysis and correlation study of anaemia in patients with maintenance haemodialysis[J]. Chinese Journal of General Practice, 2021, 19(5): 871-874. doi: 10.16766/j.cnki.issn.1674-4152.001938
[2]	ICARDI A, PAOLETTI E, DE NICOLA L, et al. Renal anaemia and EPO hypo-responsiveness associated with vitamin D deficiency: the potential role of inflammation[J]. Nephrol Dial Transplant, 2013, 28(7): 1672-1679. doi: 10.1093/ndt/gft021
[3]	DROZDZ M, WEIGERT A, SILVA F, et al. Achievement of renal anemia KDIGO targets by two different clinical strategies: a European hemodialysis multicenter analysis[J]. BMC Nephrol, 2019, 20(1): 5. doi: 10.1186/s12882-018-1196-7
[4]	MIMA A. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: advantages and disadvantages[J]. Eur J Pharmacol, 2021, 912: 174583. DOI: 10.1016/j.ejphar.2021.174583.
[5]	HARLOW C E, GANDAWIJAYA J, BAMFORD R A, et al. Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic predictor for EPO-increasing therapies[J]. Am J Hum Genet, 2022, 109(9): 1638-1652. doi: 10.1016/j.ajhg.2022.08.004
[6]	CHEN N, HAO C, PENG X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis[J]. N Engl J Med, 2019, 381(11): 1001-1010. doi: 10.1056/NEJMoa1813599
[7]	ZHANG L, HOU J, LI J, et al. Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis[J]. Aging (Albany NY), 2021, 13(13): 17914-17929.
[8]	CHEN N, HAO C, LIU B C, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis[J]. N Engl J Med, 2019, 381(11): 1011-1022. doi: 10.1056/NEJMoa1901713
[9]	LI J, HAASE V H, HAO C M. Updates on hypoxia-inducible factor prolyl hydroxylase inhibitors in the treatment of renal anemia[J]. Kidney Dis (Basel), 2023, 9(1): 1-11. doi: 10.1159/000527835
[10]	ZHENG X, JIN Y, XU T, et al. Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: a cohort study[J]. Ren Fail, 2023, 45(1): 2199093. DOI: 10.1080/0886022X.2023.2199093.
[11]	ICHII M, MORI K, MIYAOKA D, et al. Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis[J]. BMC Nephrol, 2021, 22(1): 104. doi: 10.1186/s12882-021-02304-2
[12]	TOKUYAMA A, KADOYA H, OBATA A, et al. Roxadustat and thyroid-stimulating hormone suppression[J]. Clin Kidney J, 2021, 14(5): 1472-1474. doi: 10.1093/ckj/sfab007
[13]	HARAGUCHI T, HAMAMOTO Y, KUWATA H, et al. Effect of roxadustat on thyroid function in patients with renal anemia[J]. J Clin Endocrinol Metab, 2023, 109(1): e69-e75. doi: 10.1210/clinem/dgad483
[14]	YAO B, WEI Y, ZHANG S, et al. Revealing a mutant-induced receptor allosteric mechanism for the thyroid hormone resistance[J]. iScience, 2019, 20: 489-496. doi: 10.1016/j.isci.2019.10.002
[15]	VARGHESE T, REJJSH K V, ANAND G, et al. Dietary GABA enhances hypoxia tolerance of a bottom-dwelling carp, Cirrhinus mrigala by modulating HIF-1alpha, thyroid hormones and metabolic responses[J]. Fish Physiol Biochem, 2020, 46(1): 199-212. doi: 10.1007/s10695-019-00708-4